Degron Therapeutics Co.
Latest round
- Series A
Last raised
- May 2026
Total raised
- $82M
Investors
- 21
About Degron Therapeutics Co.
, Ltd, doing business as Degron Therapeutics, operates as a developer of targeted protein degradation technology and new drugs. The company's CEO and Co-founder, Lily Zou, who graduated from Beijing University and served as CEO of Fosun Pharma. It reached a multi-target cooperative research and development and exclusive licensing agreement with Takeda Pharmaceutical Company Limited. Degron Therapeutics develops molecular glue degrader compound libraries and targeted protein degradation platforms for drug discovery. Its offerings include molecular glue screening services, phenotypic screening, protein profiling, and in vitro and in vivo target discovery and validation technologies supporting oncology, immune and metabolic disease research programs. he company generates revenue through research collaborations, licensing agreements, and the development of small molecule protein degraders for therapeutic applications, primarily working with pharmaceutical partners on discovery and preclinical development programs. The company plans to advance multiple molecular glue degrader programs into clinical development, expand its targeted protein degradation pipeline across oncology, immunology, and metabolic diseases.
Who invested in Degron Therapeutics Co.
21 investors across 4 rounds
See all investors in Degron Therapeutics Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Degron Therapeutics Co.
Who invested in Degron Therapeutics Co.?
Degron Therapeutics Co. has 21 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Degron Therapeutics Co. raised?
Degron Therapeutics Co. has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Degron Therapeutics Co. last raise money?
Degron Therapeutics Co.'s most recent round on record is a Series A, in May 2026.
What does Degron Therapeutics Co. do?
, Ltd, doing business as Degron Therapeutics, operates as a developer of targeted protein degradation technology and new drugs.
Where is Degron Therapeutics Co. headquartered?
Degron Therapeutics Co. is headquartered in Shanghai, China.
Which VCs invest in companies like Degron Therapeutics Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Degron Therapeutics Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Degron Therapeutics Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.